![Kreske Nickelsen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kreske Nickelsen
Amministratore Delegato presso Joint Polish Investment Fund Management BV
Profilo
Kreske Nickelsen is currently the General Partner & Chief Executive Officer at Joint Polish Investment Fund Management BV and also serves as a Director at pHase2 microtechnologies, Inc. In the past, she served as the Chairman-Supervisory Board at ProtAffin Biotechnologie AG and as a Director-Supervisory Board at F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH.
She was also an Investment Partner at Aescap Venture Management BV from 2006 to 2011.
Ms. Nickelsen holds an MBA degree from INSEAD.
Posizioni attive di Kreske Nickelsen
Società | Posizione | Inizio |
---|---|---|
Joint Polish Investment Fund Management BV
![]() Joint Polish Investment Fund Management BV Investment ManagersFinance Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands. | Amministratore Delegato | 01/01/2015 |
Phase2 Microtechnologies, Inc.
![]() Phase2 Microtechnologies, Inc. Electronic ComponentsElectronic Technology Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Kreske Nickelsen
Società | Posizione | Fine |
---|---|---|
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Presidente | 17/02/2014 |
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Investitore di Private Equity | 01/11/2011 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Direttore/Membro del Consiglio | - |
Formazione di Kreske Nickelsen
INSEAD | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
Aescap Venture Management BV
![]() Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
ProtAffin Biotechnologie AG
![]() ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
![]() F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Joint Polish Investment Fund Management BV
![]() Joint Polish Investment Fund Management BV Investment ManagersFinance Joint Polish Investment Fund Management BV (Joint Polish Investment Fund Management) is a venture capital firm founded in 2015. The firm headquartered in Netherlands. | Finance |
Phase2 Microtechnologies, Inc.
![]() Phase2 Microtechnologies, Inc. Electronic ComponentsElectronic Technology Phase2 Microtechnologies, Inc. is a technology development company that offers Micro-Electro-Mechanical Systems-enabled pH sensor technology platforms. The company was founded in 2016 and is headquartered in Pittsburgh, PA. | Electronic Technology |
- Borsa valori
- Insiders
- Kreske Nickelsen